| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Anti-tumor effect of combination of retinoid (Am80) and histone deacetylase inhibitor MS-275(entinostat) in a cutaneous T cell lymphoma cell line (SeAx) was examined from the point of restoration of tumor suppressor gene retinoic acid receptor (RAR)β2 via histone acetylation. RARβ2 gene expression was restored only by the combination rather than by either of the agents singly. The combination treatment significantly inhibited cell growth in vitro, suppressed subcutaneously transplanted tumor growth, and prolonged survival of tumor-bearing mice in vivo. In the combination treatment, the histone H4 acetylation level in the promoter region increased after restoration of RARβ2 expression.
(Kato Y, Egusa C, Maeda T, Tsuboi R: Anti-tumor effect of combination of retinoid and histone deacetylase inhibitor in cutaneous T cell lymphoma cell is due to restoration of tumor suppressor gene retinoic acid receptor β2 via histone acetylation (Submitted).
|
